Avego BioScience Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Co-investorsTSVCAbingworthIkarian Capital
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BoardZach Scheiner(Director)inMegan Krench(Director)Dmitrij Hristodorov(Director)in
Co-investorsSanofi VenturesForbionRA CapitalSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.